Research Analysts’ Recent Ratings Changes for Ligand Pharmaceuticals (LGND)

Several brokerages have updated their recommendations and price targets on shares of Ligand Pharmaceuticals (NASDAQ: LGND) in the last few weeks:

  • 11/11/2026 – Ligand Pharmaceuticals had its price target raised by Barclays from $345.00 to $350.00. They now have an “overweight” rating on the stock.
  • 11/5/2026 – Ligand Pharmaceuticals had its price target raised by Citigroup from $397.00 to $402.00. They now have a “buy” rating on the stock.
  • 11/2/2026 – Ligand Pharmaceuticals was downgraded by Weiss Ratings from “buy (b)” to “hold (c)”.
  • 10/30/2026 – Ligand Pharmaceuticals had its price target raised by Royal Bank Of Canada from $345.00 to $357.00. They now have an “outperform” rating on the stock.
  • 9/25/2026 – Ligand Pharmaceuticals is now covered by Barclays. They set an “overweight” rating and a $345.00 price target on the stock.
  • 9/24/2026 – Ligand Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright. They now have a $358.00 price target on the stock.
  • 9/23/2026 – Ligand Pharmaceuticals had its price target raised by Citigroup from $390.00 to $397.00. They now have a “buy” rating on the stock.
  • 9/21/2026 – Ligand Pharmaceuticals was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.

Ligand Pharmaceuticals Stock Performance

Shares of LGND traded up $2.88 during mid-day trading on Wednesday, hitting $296.69. 26,556 shares of the company’s stock were exchanged, compared to its average volume of 263,004. The business’s 50 day moving average is $302.13 and its two-hundred day moving average is $259.07. The company has a current ratio of 1.22, a quick ratio of 1.19 and a debt-to-equity ratio of 0.71. The firm has a market capitalization of $5.93 billion, a P/E ratio of 132.45, a P/E/G ratio of 5.27 and a beta of 1.16. Ligand Pharmaceuticals Incorporated has a fifty-two week low of $175.89 and a fifty-two week high of $326.63.

Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The biotechnology company reported $2.67 earnings per share for the quarter, topping analysts’ consensus estimates of $2.33 by $0.34. The firm had revenue of $78.75 million for the quarter, compared to analyst estimates of $77.00 million. Ligand Pharmaceuticals had a return on equity of 5.22% and a net margin of 20.27%. Ligand Pharmaceuticals’s quarterly revenue was down 31.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.09 earnings per share. On average, equities analysts expect that Ligand Pharmaceuticals Incorporated will post 2.35 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director John Kozarich sold 500 shares of the business’s stock in a transaction that occurred on Thursday, November 12th. The shares were sold at an average price of $325.00, for a total value of $162,500.00. Following the completion of the sale, the director directly owned 42,122 shares in the company, valued at approximately $13,689,650. The trade was a 1.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jason Aryeh sold 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 10th. The stock was sold at an average price of $320.05, for a total transaction of $960,150.00. Following the sale, the director owned 105,476 shares of the company’s stock, valued at approximately $33,757,593.80. This represents a 2.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 24,093 shares of company stock worth $7,384,287 over the last 90 days. Corporate insiders own 5.60% of the company’s stock.

Ligand Pharmaceuticals is a biopharmaceutical company that works with pharmaceutical and biotechnology partners to develop and commercialize medicines. Rather than focusing primarily on selling drugs directly, Ligand licenses technologies and drug-development assets and may receive royalties and other payments from partner programs. Its technologies include Captisol, a formulation platform designed to improve the solubility and delivery of certain medicines. Ligand also holds economic interests in a portfolio of partnered products and drug candidates across multiple therapeutic areas.

Featured Stories

Receive News & Ratings for Ligand Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.